Novavax Inc（NVAX）股票分析NVAXNovavax Inc

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Novavax Inc is a good buy right now due to its recent vaccine approvals which are expected to generate significant revenue. The current price is $9.26, with a forward P/E ratio of 2.58 indicating potential for growth. Additionally, the stock has shown a year-to-date change of +29.87%, reflecting strong market sentiment. However, the main risk is its recent financial performance, particularly a net income loss of $53.39 million in Q2 2026, which could affect future profitability.

7 analysts cover NVAX: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 10.50.